Related references
Note: Only part of the references are listed.Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
Els L. van Persijn van Meerten et al.
EUROPEAN RADIOLOGY (2010)
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
Geraldine Perkins et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Role of Src family kinases in acquired resistance to EGFR therapies in cancer
Julie L. Boerner
CANCER BIOLOGY & THERAPY (2009)
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab
Deric L. Wheeler et al.
CANCER BIOLOGY & THERAPY (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
S. Gattenloehner et al.
JOURNAL OF ONCOLOGY (2009)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Daniele Santini et al.
ONCOLOGIST (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers
J. Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Epithelial-mesenchymal transition in development and cancer:: role of phosphatidylinositol 3′ kinase/AKT pathways
L Larue et al.
ONCOGENE (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
